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A B S T R A C T   
Background: Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. 
Objective: We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and 
COVID-19 in-hospital mortality. 
Methods: In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in 
Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. 
The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ 
with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse 
probability for treatment weighting by propensity scores, with the addition of subgroup analyses. 
Results: Out of 3,451 COVID-19 patients, 76.3% received HCQ. Death rates (per 1,000 person-days) for patients 
receiving or not HCQ were 8.9 and 15.7, respectively. After adjustment for propensity scores, we found 30% 
lower risk of death in patients receiving HCQ (HR=0.70; 95%CI: 0.59 to 0.84; E-value=1.67). Secondary 
analyses yielded similar results. The inverse association of HCQ with inpatient mortality was particularly evident 
in patients having elevated C-reactive protein at entry. 
Conclusions: HCQ use was associated with a 30% lower risk of death in COVID-19 hospitalized patients. Within 
the limits of an observational study and awaiting results from randomized controlled trials, these data do not 
discourage the use of HCQ in inpatients with COVID-19.   
1. Introduction 
The aminoquinoline hydroxychloroquine (HCQ) has been ex-
tensively used in the treatment of malaria and is currently widely used 
to treat autoimmune diseases like rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), due 
to its immunomodulatory and anti-thrombotic properties [1]. More 
recently, a promising role of HCQ has been suggested in viral infections  
[2], since it directly inhibits viral entry and spread in several in 
vitro and in vivo models. Due to these properties, HCQ has been used in 
Ebola virus disease [3, 4], human immunodeficiency virus (HIV) in-
fection [5], SARS-CoV-1 infection and the Middle East Respiratory 
Syndrome (MERS) [6, 7] and gained worldwide attention as a possible 
therapy in COVID-19 patients [8]. 
HCQ might inhibit the intracellular glycosylation of ACE 2, the re-
ceptor used by the SARS-CoV-2 virus to enter the cells, resulting in a 
reduced ligand recognition and internalization of the virus [7] and 
exerting a possible protective role in SARS-CoV-2 infection. Moreover, 
due to its immunomodulatory, anti-inflammatory and anti-thrombotic 
effects, HCQ could also modulate the severity of the disease. However, 
the exact mechanism for the potential benefit in COVID-19 is largely 
speculative [9] and might be counterbalanced by adverse effects, 
mainly cardiovascular [10, 11], so that the net balance of this drug's use 
remains to be established. 
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The American Food and Drug Administration (FDA) allowed 
Chloroquine (CQ) phosphate and HCQ to be provided to certain hos-
pitalized patients because these drugs may possibly help patients with 
severe COVID-19 [12]. The European Medicines Agency (EMA) au-
thorized the use of CQ and HCQ for COVID-19 in clinical trials or as 
emergency use [13], while the Italian Drug Agency (AIFA) stated in this 
emergency phase that therapeutic use of HCQ might be considered in 
COVID-19 patients, both in those with mild presentation managed at 
home and in hospitalized patients [14]. In clinical practice, HCQ rather 
than chloroquine has been used because of its more potent antiviral 
properties and better safety profile [15]. 
However, in the light of a recent publication [16], that was later 
retracted [17], on the lack of safety and efficacy of HCQ in the treat-
ment for COVID-19 patients the Executive Group of the Solidarity Trial 
decided to implement a temporary pause of the HCQ arm within the 
trial as a precaution, while the safety data is being reviewed [18]. Si-
milarly, the Italian drug Agency AIFA decided to suspend the author-
ization to use HCQ for COVID-19 treatment outside clinical trials [19]. 
Recent reviews of clinical trials or observational studies [20–24] 
have reported insufficient and often conflicting evidence on the benefits 
and harms of using HCQ to treat COVID-19 and concluded that as such, 
it was impossible to determine the balance of benefits to harm. Until 
now, although several trials had been started on the use of CQ and HCQ 
in COVID-19, only few of them have been published [25] on small 
numbers of patients or on surrogate endpoints or in exposed subjects for 
prophylaxis use [26]. 
While waiting the results from ongoing randomized clinical trials 
(RCT) to define the efficacy in preventing hard endpoints of this 
treatment so widely used during the emergency phase of the COVID-19 
pandemic, powered retrospective observational studies performed in 
different geographical and disease conditions may still be useful to shed 
light on this debate. Two retrospective observational studies, both 
conducted in the New York metropolitan region, did not report any 
significant association between HCQ use and rates of intubation or 
death [27, 28]. 
No data are presently available from large cohorts of patients in 
Italy, which represents one of the most affected countries in terms of 
total deaths for COVID-19 in the world [29]. We undertook a multi-
center Italian collaboration [30] to investigate the relationship between 
underlying risk factors and COVID-19 outcomes, and to evaluate the 
association between different drug therapy and disease severity and/or 
mortality. We report here the results obtained in 3,451 hospitalized 
COVID -19 patients receiving or not HCQ treatment. 
2. Material and methods 
2.1. Setting 
This national retrospective observational study was conceived, co-
ordinated and analysed within the CORIST Project (ClinicalTrials.gov 
ID: NCT04318418, 30]. The study was approved by the institutional 
ethics board of the Istituto di Ricovero e Cura a Carattere Scientifico 
(IRCCS) Neuromed, Pozzilli, and of all recruiting centres. Data for the 
present analyses were provided by 33 hospitals distributed throughout 
Italy (listed in the supplementary file). Acceptance to participate in the 
project or to provide data for the present analysis was not related to the 
use of CQ/HCQ. Each hospital provided data from hospitalized patients 
who had a positive test result for the SARS-CoV-2 virus at any time 
during their hospitalization from February 19 to May 23, 2020. The 
follow-up continued through May 29, 2020. 
2.2. Data sources 
We developed a cohort comprising 3,971 patients with laboratory- 
confirmed SARS-CoV-2 infection in an in-patient setting. The SARS- 
CoV-2 status was declared based on laboratory results (polymerase 
chain reaction on nasopharyngeal swab) from each participating hos-
pital. Clinical data were abstracted at one-time point from electronic 
medical records or charts, and were collected using either a centrally 
designed electronic worksheet or a centralized web-based database. 
Collected data included patients’ demographics, laboratory test results, 
medication administration, historical and current medication lists, 
historical and current diagnoses, and clinical notes. In addition, specific 
information on the most severe manifestation of COVID-19 occurred 
during hospitalization was retrospectively captured. Maximum clinical 
severity observed was classified as mild pneumonia; or severe pneu-
monia; or acute respiratory distress syndrome (ARDS) [31]. Specifi-
cally, we obtained the following information for each patient: hospital; 
date of admission and date of discharge or death; age; sex; the first 
recorded inpatient laboratory tests at the entry (creatinine, C-reactive 
protein); past and current diagnoses (myocardial infarction, heart 
failure, diabetes, hypertension, respiratory disease and cancer) and 
current drug therapies for COVID-19 – HCQ, lopinavir/ritonavir or 
darunavir/cobicistat, remdesevir, tocilizumab or sarilumab, corticos-
teroids, heparin, and for comorbidities (insulin, anti-hypertensive 
treatments, aldosterone receptor antagonists, diuretics, statins, sacubi-
tril/valsartan). A diagnosis of pre-existing cardiovascular disease was 
based on history of myocardial infarction or heart failure. Chronic 
kidney disease was classified as: stage 1: kidney damage with normal or 
increased glomerular filtration rate (GFR) (>90 mL/min/1.73 m2); 
stage 2: mild reduction in GFR (60-89 mL/min/1.73 m2); stage 3a: 
moderate reduction in GFR (45-59 mL/min/1.73 m2); stage 3b: mod-
erate reduction in GFR (30-44 mL/min/1.73 m2); stage 4: severe re-
duction in GFR (15-29 mL/min/1.73 m2); stage 5: kidney failure (GFR 
<15 mL/min/1.73 m2 or dialysis). For statistical analysis, stages 3a 
and 3b and stages 4 and 5 were combined. GFR was calculated by the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equa-
tion. Patients were defined as receiving HCQ if they were receiving it at 
admission to hospital or received it during the follow-up period. Ac-
cording to the AIFA guidance [14], HCQ was administered at dose of 
400 mg x 2/day or x4/day the first day, and 200 mg x 2/day from the 
second day onwards for at least 5 to a maximum of 10 days, according 
to the clinical evolution of the disease. 
2.3. Statistical analysis 
The study index date was defined as the date of hospital admission. 
Index dates ranged from February 19, 2020 to May 23, 2020. The study 
end point was the time from study index to death. The number of pa-
tients who either died, or had been discharged alive, or were still ad-
mitted to hospital as of May 29, 2020, were recorded, and hospital 
length of stay was determined. Patients alive had their data censored on 
the date of discharge or as the date of the respective clinical data col-
lection. Data were censored at 35 days of follow up in n=330 (8.3%) 
patients with a follow up greater than 35 days. 
Of the initial cohort of 3,971 patients, 350 patients were excluded 
from the analysis because they had at least one missing data at baseline 
or lost to follow up on HCQ use (N=94), other drug therapies for 
COVID-19 (n=265), time to event (n=59), outcome (death/alive, 
n=8), COVID-19 severity (n=4), age (n=4 with missing data and n=2 
with age<18 years) or sex (n=2). Of the remaining 3,621 patients, 170 
patients died or were discharged within 24 hours after presentation, 
and were also excluded from the analysis. 
At the end, the analysed cohort consisted of n=3,451 patients. In 
patients not included in the analysis (n=520), as unique difference 
with the analysed group, the prevalence of diabetics (19.9% vs 14.8%, 
P=0.0066) and, to a less extent, of men (62.3% vs 58.3%, P=0.081) 
was higher. Out of 3,541 patients, 295 (8.5%) had at least a missing 
value for covariates. Distribution of missing values was as follows: 
n=178 for C-reactive protein; n=69 for GFR; n=74 for history of is-
chemic disease; n=64 for history of chronic pulmonary disease; n=51 
for diabetes; n=51 for hypertension and n=56 for cancer. We used 
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multiple imputation techniques (SAS PROC MI, n=10 imputed data-
sets; and PROC MIANALYZE) to maximize data availability. As sensi-
tivity analysis, we also conducted a case-complete analysis on 3,156 
patients. 
Cox proportional-hazards regression models were used to estimate 
the association between HCQ use and death. Since multiple imputation 
was applied, the final standard error was obtained using the Rubin's 
rule based on the robust variance estimator in Cox regression [32]. The 
proportional hazards assumption was assessed using weighed Schoen-
feld residuals, and no violation was identified. To account for the non- 
randomized HCQ administration and to reduce the effects of con-
founding, the propensity-score method was used. The individual pro-
pensities for receiving HCQ treatment were assessed with the use of a 
multivariable logistic-regression model that included age, sex, diabetes, 
hypertension, history of ischemic heart disease, chronic pulmonary 
disease, GFR, C-reactive protein, hospitals clustering and use of other 
drug therapies for COVID-19 (lopinavir/ritonavir or darunavir/cobici-
stat, remdesivir, corticosteroids, tocilizumab or sarilumab). Associa-
tions between HCQ treatment and death was then appraised by multi-
variable Cox regression models with the use of propensity-score and 
further controlling for hospitals clustering as random effect (frailty 
model). The use of a frailty model was chosen as suggested in [33]. The 
primary analysis used inverse probability by treatment weighting; the 
predicted probabilities from the propensity-score model was used to 
calculate the stabilized inverse-probability-weighting weight [34]. 
Stabilized weights were normalized so that they added up the actual 
sample size. Secondary analyses used propensity-score stratification 
(n=5 strata) or multivariable Cox regression analysis or multivariable 
logistic regression analyses comparing death versus alive patients, or 
accounted for hospitals clustering via stratification or by robust sand-
wich estimator. Pre-established subgroup analyses were conducted ac-
cording to age or sex of patients, degree of COVID-19 severity experi-
enced during the hospital stay, C-reactive protein at basal or other drug 
therapies for COVID-19. Hospitals were clustered according to their 
geographical distribution, as illustrated in Table 1. To quantify the 
potential for an unmeasured confounder to render apparent statistically 
significant hazard ratio non-significant, the E-value was calculated  
[35]. Analyses were performed with the aid of the SAS version 9.4 
statistical software for Windows. 
3. Results 
We included in the final current analyses 3,451 patients who were 
hospitalized with confirmed SARS-CoV-2 infection at 33 clinical centres 
across Italy and either died, had been discharged, or were still in hos-
pital as of May 29, 2020. Of these patients, 2,634 (76.3%, range among 
hospitals 53.2% to 93.6%) received HCQ. Timing of the first dose of 
HCQ after presentation to the hospital was 1 day for the large majority 
of centres, and 2 to 3 days for the others. HCQ was administered in all 
centres at the dose of 400 mg/day (in one centre however it was used at 
the dose of 600 mg/day and in another at the dose of 600 mg/day but 
only in patients younger than 65 years). Duration of treatment ranged 
from 5 to 15 days (with 10 days as the modal value). The drug used was 
HCQ in all hospitals. 
Baseline characteristics according to HCQ use are shown in Table 1. 
Patients receiving HCQ were more likely younger, men and had higher 
Table 1 
General characteristics of COVID-19 patients at baseline, according to hydro-
xychloroquine use.       
Hydroxychloroquine   
Characteristic No (N=817) Yes (N=2,634) P-value 
unadjusted* 
Age-median (IQR-yr.) 73 (58-83) 66 (55-77) <.0001 
Gender- no (%)   <.0001 
Women 361 (44.2%) 940 (36.7%)  
Men 456 (55.8%) 1,694 (64.3%)  
Diabetes- no (%)   0.71 
No 633 (77.5%) 2,090 (79.3%)  
Yes 162 (19.9%) 515 (19.6%)  
missing data 22 (2.7%) 29 (1.1%)  
Hypertension - no (%)   0.31 
No 378 (46.3%) 1,294 (49.1%)  
Yes 416 (50.9%) 1,312 (49.8%)  
missing data 23 (2.7%) 28 (1.1%)  
Ischemic heart disease- no 
(%)   
<.0001 
No 610 (74.7%) 2,190 (83.1%)  
Yes 179 (21.9%) 398 (15.1%)  
missing data 28 (3.4%) 46 (1.8%)  
Chronic pulmonary 
disease- no (%)   
0.21 
No 666 (81.5%) 2,225 (84.5%)  
Yes 127 (15.5%) 369 (14.0%)  
missing data 24 (2.9%) 40 (1.5%)  
Cancer- no (%)   0.036 
No 694 (84.9%) 2,338 (88.8%)  
Yes 101 (12.4%) 262 (9.9%)  
missing data 22 (2.6%) 34 (1.3%)  
CKD stage**- no (%)   <.0001 
Stage 1 241 (29.5%) 970 (36.8%)  
Stage 2 281 (34.4%) 991 (37.6%)  
Stage 3a or stage 3b 180 (22.0%) 487 (18.5%)  
Stage 4 or stage 5 89 (10.9%) 143 (5.4%)  
missing data 26 (3.2%) 43 (1.6%)  
C Reactive Protein- no (%)   0.0003 
<1 mg/L 104 (12.7%) 256 (9.7%)  
1-3 mg/L 120 (14.7%) 301 (11.4%)  
>3 mg/L 549 (67.2%) 1,943 (73.8%)  
missing data 44 (5.4%) 134 (5.1%)  
Lopinavir or Darunavir 
use   
<.0001 
No 621 (76.0%) 1,203 (36.7%)  
Yes 196 (24.0%) 1,431 (64.3%)  
Tocilizumab or Sarilumab 
use   
<.0001 
No 755 (92.4%) 2,160 (82.0%)  
Yes 62 (7.6%) 474 (18.0%)  
Remdesivir use   0.0015 
No 808 (98.9%) 2,551 (96.9%)  
Yes 9 (1.1%) 83 (3.1%)  
Corticosteroids use   <.0001 
No 596 (73.0%) 1,655 (62.8%)  
Yes 221 (27.0%) 979 (37.2%)  
Clusters of hospitals   <.0001 
Northern regions (except 
Milan) (n) 
169 (20.7%) 616 (23.4%)   
Table 1 (continued)      
Hydroxychloroquine   
Milan (m) 161 (19.7%) 525 (19.9%)  
Center regions (except 
Rome) (c)) 
303 (37.1%) 747 (28.4%)  
Rome (r) 94 (11.5%) 390 (14.8%)  
Southern regions (s) 90 (11.0%) 356 (13.5%)  
(n) include hospitals of Novara, Monza, Varese, Pavia, Cremona and Padova; 
(m) include Humanitas Clinical and Research Hospital, Centro Cardiologico 
Monzino, and hospitals of San Donato Milanese (Milano) and Cinisello Balsamo 
(Milano); (c) include hospitals of Modena, Ravenna, Forlì, Firenze, Pisa, Chieti 
and Pescara; (r) include National Institute for Infectious Diseases “L. 
Spallanzani” and Università Cattolica del Sacro Cuore; (s) include hospital of 
Napoli, Pozzilli (Isernia), Acquaviva delle Fonti (Bari), Foggia, Taranto, 
Catanzaro, Catania and Palermo 
*Chi-square test. **Stage 1: Kidney damage with normal or increased glo-
merular filtration rate (GFR) (>90 mL/min/1.73 m2); Stage 2: Mild reduction 
in GFR (60-89 mL/min/1.73 m2); Stage 3a: Moderate reduction in GFR (45-59 
mL/min/1.73 m2); Stage 3b: Moderate reduction in GFR (30-44 mL/min/1.73 
m2); Stage 4: Severe reduction in GFR (15-29 mL/min/1.73 m2); Stage 5: 
Kidney failure (GFR < 15 mL/min/1.73 m2 or dialysis).  
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levels of C-reactive protein and less likely had ischemic heart disease, 
cancer or stages 3a or greater chronic kidney disease (Table 1). Patients 
receiving HCQ more likely received another drug for COVID-19 treat-
ment (78.4%; lopinavir/ritonavir or darunavir/cobicistat, remdesevir, 
tocilizumab or sarilumab, corticosteroids), in comparison with non- 
HCQ patients (46.3%; P<0.0001; Table 1). 
The unadjusted differences and differences adjusted by propensity 
scores between HCQ-treated and non-HCQ treated patients for each 
variable included in the propensity score are shown in Fig. 1. All the 
pre-treatment differences disappeared after adjustment by propensity 
score weighting. The C-statistic of the propensity-score model was 0.74. 
3.1. Primary outcome 
Out of 3,628 patients, 576 died (16.7%), 2,390 were discharged 
alive (69.3%) and 485 (14.1%) were still at the hospital. The median 
follow-up was 14 days (interquartile range 8 to 22; range 2 to 35; 
55,388 person-days). Death rate (per 1,000 person-days) was 8.9 in 
HCQ and 15.7 in non-HCQ patients (Table 2). At univariable analysis, 
hazard ratio for mortality was 0.56 (95%CI: 0.47 to 0.67). In the pri-
mary multivariable analysis with inverse probability weighting ac-
cording to the propensity score, HCQ use was associated with a 30% 
(95%CI: 16% to 41%) reduction in death risk (Fig. 2, Table 2, E- 
value=1.67). Secondary multivariable analyses yielded very similar 
results (Table 2), as well as case-complete analyses restricted to the 
3,156 patients without missing data (Table 2). Considering secondary 
multivariable analyses overall, HR for mortality associated with HCQ 
ranged between 0.64 to 0.70, according to type of analyses. Control of 
hospitals clustering with different approaches also yielded similar re-
sults for the primary analysis (HR=0.71, 95%CI: 0.59 to 0.85 when 
hospitals clustering was stratified for and HR=0.69, 95%CI: 0.54 to 
0.88 with the robust sandwich estimator). 
Subgroup analyses are presented in Table 3. HCQ use remained 
consistently associated with reduced mortality in almost all subgroups. 
The inverse association of HCQ with inpatient mortality is slightly more 
evident in women, elderly and in patients who experienced a higher 
degree of COVID-19 severity. It was absent in-patient with C-reactive 
protein <10 mg/L and clearly confined to patients with elevated C- 
reactive protein (Table 3). 
4. Discussion 
In a large cohort of 3,451 patients hospitalized for COVID-19 in 33 
clinical centers all over Italy, covering almost completely the period of 
the hospitalization for COVID-19, the use of HCQ was associated with a 
significant better survival. In-hospital crude death rate was 8.9 per 
1,000 person-day for patients receiving HCQ and 15.7 for those who did 
not. After adjustment for known possible confounders, we observed a 
30% reduction in the risk of death in patients receiving HCQ therapy as 
compared with those who did not. 
Our findings provide clinical evidence in support of guidelines by 
Italian and several international Societies suggesting to use HCQ 
therapy in patients with COVID-19. However, the observed associations 
should be considered with caution, as the observational design of our 
study does not allow to fully excluding the possibility of residual con-
founders. Large randomized clinical trials in well-defined geographical 
and socio-economic conditions and in well-characterized COVID-19 
patients, should evaluate the role of HCQ before any firm conclusion 
can be reached regarding a potential benefit of this drug in patients 
with COVID-19. 
Over 76% of patients received HCQ either alone or in combination 
with other drugs. They were more likely to be younger, men and with 
higher levels of C reactive protein at entry, while less likely had pre- 
existing comorbidities such as ischemic heart disease, cancer and severe 
chronic kidney disease, as compared to patients not receiving the drug. 
We adjusted our analyses for possible confounders, including age, sex, 
diabetes, hypertension, history of ischemic heart disease, chronic pul-
monary disease, chronic kidney disease, C-reactive protein and addi-
tional treatments for COVID-19, and took into account possible differ-
ences across centres by either adjustment or stratification. To minimize 
bias due to the observational design, we used different analytical ap-
proaches aiming at creating an overall balance between comparison 
Fig. 1. The unadjusted standardized differences and standardized differences adjusted by propensity scores between HCQ-treated and non-HCQ treated patients for 
the variables included in the propensity score. All differences for the matched observations are within the recommended limits of –0.25 and 0.25, which are indicated 
by reference lines. 
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groups. Finally, we tried to limit bias due to missing data by using a 
multiple imputation approach, but in no case, the result was changed. 
Despite all these precautions, we recognize the possibility, however, of 
residual unmeasured confounders affecting results. 
Systematic reviews of small clinical trials had reported contrasting 
results that were however scarcely reliable because of poor designs  
[20–25]. The HCQ doses tested in a Chinese randomized clinical trial  
[25] were approximately double as compared to that used in our study 
(1200 mg vs 800 mg as loading dose, 800 mg vs 400 mg as maintenance 
dose) for twice the time (14-21 days versus 7-10 days). National 
guidelines in Italy suggest to use HCQ 200 mg twice daily for at least 5- 
7 days in patients over 70 years and/or with co-morbidities (chronic 
obstructive pulmonary disease, diabetes, cardiovascular disease) even 
with mild respiratory symptoms or with radiographically documented 
pneumonia or in severe patients [36]. The lower doses of HCQ used in 
our centers, as suggested by Italian official guidelines [19, 36], may 
have been both more effective and safer. 
Two recently published large observational studies, both from large 
Table 2 
Incidence rates and hazard ratios for death in COVID-19 patients, according to hydroxychloroquine use.       
Multiple imputation analysis (N=3,451)  
Death (N=576) Patient at risk (N=3,451) Person-days Death Rate (x1,000 person-days)  
Hydroxychloroquine     
No- no. (%) 190 (23.3%) 817 (100%) 12,084 15.7 
Yes- no. (%) 386 (14.7%) 2,634 (100%) 43,304 8.9 
Hazard ratio for death (HCQ versus non HCQ) HR (95% CI) 
Crude analysis 0.56 (0.47 to 0.67) 
Multivariable analysis* 0.70 (0.58 to 0.85) 
Propensity score analysis, inverse probability weighting** (primary analysis) 0.70 (0.59 to 0.84) 
Propensity score analysis, stratification (n=5 strata)** 0.67 (0.56 to 0.81) 
Odds ratio for death (HCQ versus non HCQ) OR (95% CI) 
Propensity score analysis, inverse probability weighting** 0.67 (0.54 to 0.82) 
Case Complete Analysis (N=3,156)  
Death (N=510) Patient at risk (N= 3,156) Person-days Death Rate (x1,000 person-days) 
Hydroxychloroquine     
No- no. (%) 170 (22.9%) 741 (100%) 11,050 15.4 
Yes- no. (%) 340 (14.1%) 2,415 (100%) 39,274 8.7 
Hazard ratio for death (HCQ versus non HCQ) HR (95% CI) 
Crude analysis 0.56 (0.46 to 0.67) 
Multivariable analysis* 0.71 (0.59 to 0.86) 
Propensity score analysis, inverse probability weighting** 0.64 (0.53 to 0.76) 
Propensity score analysis, stratification (n=5 strata)** 0.68 (0.56 to 0.82) 
Odds ratio for death (HCQ versus non HCQ) OR (95% CI) 
Propensity score analysis, inverse probability weighting** 0.67 (0.54 to 0.82) 
Abbreviations: HR, hazard ratios; CI, confidence intervals. *Controlling for age, sex, diabetes, hypertension, history of ischemic heart disease, chronic pulmonary 
disease, chronic kidney disease, C-reactive protein, lopinavir/ritonavir or darunavir/cobicistat, tocilizumab or sarilumab, remdesivir or corticosteroids use as fixed 
effects and hospitals clustering as random effect. **Including hospitals clustering as random effect covariate.  
Fig. 2. Survival curves according to hydroxychloroquine use. The curves are adjusted by propensity score analysis (inverse probability for treatment weighting) and 
hospital index as random effect, and are generated using the first imputed dataset. The other imputed datasets are similar and thus omitted. 
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hospitals in New York City, showed no association between HCQ use 
and in-hospital mortality [27, 28], and deserve specific discussion. In 
the study of Geleris et al. [27], the percentage use of HCQ was lower 
than in Italy; moreover, in both US studies [27, 28] the drug was more 
frequently administered to patients with previous illnesses and a more 
severe presentation of the disease. Our cohort included milder pneu-
monia patients than the US population, due to between-country dif-
ferences in indications to the drug for the beginning of therapy (e.g., 
mild pneumonia in Italy versus only severe pneumonia and ARDS in the 
US). Concomitant use of other drugs for COVID-19 was very low in one 
study [27] and was not reported in the other study [28]. In our cohort, 
patients receiving HCQ were more likely treated with another drug for 
COVID-19 treatment (78.4%), in comparison with non-HCQ patients 
(46.3%). Anyway, our findings are adjusted for concomitant other 
drugs use. 
While the US studies were confined to one hospital only or a defined 
relatively small area in the Country, our study included 33 hospitals 
distributed all over Italy, covering regions with a high number of cases 
and a high intra-hospital mortality and regions with a lower burden of 
the disease. The participating Italian clinical centers have different 
healthcare facilities, different size, specialization, and ownership, and 
therefore quite closely represent the real-life Italian approach to 
COVID-19. Moreover, they differed for the percentage of use of HCQ 
and for the rate of in-hospital mortality that ranged between 34.1 and 
1.5 per 1,000 persons/day. To consider this variability, we adjusted the 
analysis for recruiting center and performed a number of subgroup 
analyses. In all circumstances, the association between HCQ use and a 
reduced risk of death of about 30% was maintained. Quite interestingly, 
the inverse association of HCQ with inpatient mortality was more evi-
dent in elderly, in patients who experienced a higher degree of COVID- 
19 severity or especially having elevated C-reactive protein, suggesting 
that the anti-inflammatory potential of HCQ may have had more im-
portant role rather than its antiviral properties. HCQ, indeed, beside an 
antiviral activity, may have both anti-inflammatory and anti-throm-
botic effects [8]. This can justify its effect in reducing mortality risk, 
since Sars-Cov-2 can induce pulmonary microthrombi and coagulo-
pathy, that are a possible cause of its severity [37, 38] and the lack in 
preventing SARS-CoV-2 infection after exposure [26] 
Nevertheless, large randomized clinical trials on the efficacy of HCQ 
on hard end-points are still lacking and the largest observational study 
showing no effect in reducing mortality has been retracted [16, 17], 
Agencies have suspended clinical trials on the efficacy of HCQ on 
COVID-19 disease or have restricted its use only to patients included in 
clinical trials, in the absence of an ample, serene and balanced dis-
cussion at international level. 
Very recently, a large RCT has become available as a pre-print 
publication [39], reporting no beneficial effect of HCQ in patients 
hospitalized with COVID-19. However, the dose of HCQ used in that 
trial was almost the double of that administered in our real life con-
ditions. A reduced mortality was also observed by other observational 
studies using low or intermediate doses of HCQ [40, 41], 
Moreover, in our study patients taking HCQ more frequently re-
ceived other anti-COVID drugs, whose interaction in reducing mortality 
cannot be completely ruled-out. Of note, despite the higher dosage 
used, the RCT did not show any excess in ventricular tachycardia or 
ventricular fibrillation in the HCQ arm (39. 
Therefore, it will be very important to compare results of studies 
with different mode of use and doses of HCQ, different characteristics of 
treated and untreated patients and different academic or real-world 
conditions. 
4.1. Strengths and limitations 
A major strength of this study is the large, unselected patient sample 
from 33 hospitals, covering the entire Italian territory. Patient sampling 
covered all the overt epidemic period in Italy. Several statistical ap-
proaches were used to overcome biases due to the observational nature 
of the investigation. 
This study has however, several recognized limitations. The study 
population pertains to Italy, and the results obtained may not be ap-
plicable to other populations with a possibly different geographical and 
socio-economic conditions and natural history of COVID-19. Due to the 
retrospective nature of the study, some parameters were not available 
in all patients, and all in-hospital medications might have been not fully 
recorded. Moreover, although guidelines on the use of HCQ in COVID- 
19 patients had been published in Italy since the first phase of the 
pandemic, individual centers could have deviated from recommenda-
tions and used different doses or treatment schemes. We have no in-
formation on the HCQ doses used individually nor of their possible 
association with azithromycin. Moreover, adverse events possibly re-
lated to drug therapy were not collected, thus we cannot exclude bias 
due to therapy interruption because of side effects; we do not know 
whether some deaths could have been due to cardiovascular compli-
cations of HCQ. However, recent data on Italian wards showed that 
COVID-19 patients receiving HCQ and azithromycin had a QTc-interval 
longer than before therapy, but did not experience, during their 
Table 3 
Hazard ratios for mortality according to hydroxychloroquine use in different subgroups       
Hydroxychloroquine NO (N=817) Hydroxychloroquine YES (N=2,634)   
Subgroups No. death/patient at risk No. death/patient at risk HR (95% CI)* 
Women 80/361 116/940 0.63 (0.46 to 0.86) 
Men 110/456 270/1,694 0.74 (0.60 to 0.93) 
Age <70 years 22/357 93/1,542 0.76 (0.50 to 1.16) 
Age ≥70 years 168/460 293/1,092 0.68 (0.56 to 0.83) 
Highest degree of COVID-19 severity experienced at hospital 
Mild pneumonia or less 28/424 40/1,358 0.70 (0.41 to 1.18) 
Severe pneumonia 80/253 172/764 0.76 (0.58 to 0.99) 
Acute respiratory distress syndrome 82/140 174/512 0.68 (0.52 to 0.90) 
Use of other COVID-19 treatments^    
No 101/439 64/570 0.63 (0.45 to 0.88) 
Yes 89/378 322/2,064 0.77 (0.61 to 0.99) 
C-Reactive Protein at basal**    
<10 mg/L 56/412 125/1,138 1.23 (0.86 to 1.77) 
≥10 mg/L 123/361 241/1,362 0.59 (0.47 to 0.73) 
Abbreviations: HR, hazard ratios; CI, confidence intervals; *Propensity score analysis, inverse probability weighting, including hospital clustering as random effect 
covariate; multiple imputed analysis. 
^Lopinavir/ritonavir or darunavir/cobicistat or tocilizumab or sarilumab or remdesivir or corticosteroids. 
**Missing data for N=178. Frequencies and hazard ratios are based on a case complete analysis (N=3,273) without missing data for C-reactive Protein; multiple 
imputed analysis (N=3,451) yielded very similar results.  
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hospital stay, any arrhythmic complications, such as syncope or life- 
threatening ventricular arrhythmias [42], a finding also reported by the 
RCT mentioned above (39). 
Finally, the possibility of unmeasured residual confounding cannot 
be completely ruled-out. However, the E-value for the lower boundary 
of the confidence interval of our main result is 1.67, indicating that the 
confidence interval could be moved to include the null by a strong 
unmeasured confounder associated with both HCQ treatment and death 
with a risk ratio of 1.67-fold for each, above and beyond all the mea-
sured confounders. Weaker confounders, however, could not do so. 
5. Conclusions 
Our study, including a large real life sample of patients hospitalized 
with COVID-19 all over Italy, shows that HCQ use (200 mg twice/day) 
was associated with a 30% reduction of overall in-hospital mortality. In 
the absence of clear-cut results from controlled, randomized clinical 
trials, our data do not discourage the use of HCQ in inpatients with 
COVID-19. Given the observational design of our study, however, these 
results should be transferred with caution to clinical practice. 
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